Virological and Molecular Profile of People Living with the Human Immunodeficiency Virus Starting Dolutegravir Based Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo
Context: Despite the new recommendations “Test and Treat”, the virological and molecular parameters remain important information for Antiretroviral Treatment and adequate for monitoring of patients infected with HIV/AIDS. Objective: the Objective of this study is to present the virological and molecular profile of People Living with HIV starting Antiretroviral Therapy in Kinshasa in the era of the Dolutegravir. Methods: This was a transversal study to determine virological and molecular profile of People Living with HIV (PLHIV) starting an ARV Treatment. The patient’s inclusion period was from October 04, 2021 to February 15, 2022. A sample of 5 ml of blood was taken in a tube with EDTA anticoagulant for Molecular Biology analyzes (Viral Load and Sequencing) in all HIV patients, after reading and signing informed consent. The population was made up of adult patients over the age of 18, infected with HIV and starting ART. Results: 119 patients (56.3% of women) were included in this study, thus a sex-ratio of 1.29. The average age of patients included was 39.87 ± 12.36 years. The most represented age group is that of 36 to 45 with 37 patients (31.9%) followed by that from 26 to 35 years with 24 patients (20.7%). Out of 119 patients, 21 patients had an undetectable Viral Load (VL). The median value of VL was 4.16 log10 RNA copies/ml. 114 samples were successfully amplified. Subtype A was dominant with 23 cases (20.2%); followed by the subtype C and CRF02_AG each with 14.0%, and D (10.5 %). K65R (1.8%), T69P/N (4.4%), K70R (7.9%) and M184V (7.0%) mutations were listed as existing mutations for Nucleotide Transcriptase Inhibitors. Conclusion: 38 patients (31.93%) started the TARV with a positive virological prognosis. The subtype A remains dominant in Kinshasa with 23 cases (20.2%); followed by the subtype C and CRF02_AG each with 14.0%. For Inhibitors of Transcriptase Reverse Nucleotide; K65R, T69P/N, K70E/R and M184V mutations were found in patients’ naive of ARV Treatment.
References
[1]
United Nations AIDS Program (UNAIDS) (2020) Country Factsheets: Democratic Republic of the Congo. https://www.unaids.org/en/regionscountries/countries/democraticrepublicofthecongo
[2]
Organisation Mondiale de la Santé (OMS) (2016) Mettre fin au VIH/SIDA d’ici 2030: Cadre d’action dans la région Africaine de l’OMS 2016-2022. Organisation mondiale de la Santé, Geneva.
[3]
Programme National de Lutte contre le VIH/SIDA et les Infections Sexuellement Transmissibles (PNLS), Ministère de la Santé publique et Hygiène, République Démocratique du Congo (2017) Guide de Prise en charge intégrée du VIH en République Démocratique du Congo. https://www.pnls-rdc.org/
[4]
World Health Organization (WHO) (2015) Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization, Geneva.
[5]
Kamangu, N.E., Bulanda, I.B., Bongenya, I.B., Botomwito, T.H., Mvumbi, L.G., De Mol, P., Vaira, D., Hayette, M.-P. and Kalala, L.R. (2015) Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa. Open Access Library Journal, 2, e1564. https://doi.org/10.4236/oalib.1101564
[6]
Girum, T., Yasin, F., Wasie, A., Shumbej, T., Bekele, F. and Zeleke, B. (2020) The Effect of “Universal Test and Treat” Program on HIV Treatment Outcomes and Patient Survival Among a Cohort of Adults Taking Antiretroviral Treatment (ART) in Low Income Settings of Gurage Zone, South Ethiopia. AIDS Research and Therapy, 17, Article No. 19. https://doi.org/10.1186/s12981-020-00274-3
[7]
Losenga, L.O., Dikati, N.M., Bongenya, B.I., Ntumba, T.K., Booto, G.I., Dembo, R.D., Selenge, S.M., Nonga, J.E., Kabamba, C.A., Sombo, M.-T.A.S., Bumoko, G.M.M. and Kamangu, E.N. (2022) Sociodemographic and Anthropometric Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of the Congo. Open Access Library Journal, 9, e9056. https://doi.org/10.4236/oalib.1109056
[8]
QIAGEN (2010) QIAamp® DNA Mini and Blood Mini Handbook. 3rd Edition, QIAGEN, Venlo.
[9]
Kamangu, N.E., Mayemba, C., Mbikayi, S., Ndarabu, A., Kalala, R.L., Mvumbi, G.L. and Vaira, D. (2014) Implementation of a Classic Nested PCR DNA for HIV Diagnosis in Kinshasa. International Journal of Collaborative Research on Internal Medicine and Public Health (IJCRIMPH), 6, 145-151.
[10]
Bongenya, B.I., Bulanda, B.I. and Kamangu, E.N. (2020) Comparison of Rapid Diagnosis Test and Nested PCR for HIV Diagnosis in Kinshasa. Open Access Library Journal, 7, e6325. https://doi.org/10.4236/oalib.1106325
[11]
Kamangu, N.E. (2022) Caractérisation Moléculaire du VIH-1 à Kinshasa: Caractérisation Moléculaire du Virus de l’Immunodéficience Humaine de Type 1 et Suivi Thérapeutique des patients pris en charge à Kinshasa/République Démocratique du Congo. Editions Universitaires Européennes, Republic of Moldova.
[12]
Kamangu, N.E., Wumba, D.M.R., Situakibanza, N.T.S., Lukusa, T.P., Kapend, K.L., Mvumbi, L.G., Hayette, M.P. and Kalala, L.R. (2018) Molecular Epidemiology of Human Immunodeficiency Virus Type 1 and Therapeutic Monitoring of Patients treated in Kinshasa/Democratic Republic of the Congo. International Journal of HIV and Aids Research, 2, 6-11.
[13]
QIAGEN (2010) QIAamp® RNA Mini and Blood Mini Handbook. 3rd Edition, QIAGEN, Venlo.
[14]
Kamangu, N.E., Chatté, A., Boreux, R., Kalala, L.R., Mvumbi, L.G., De Mol, P., Vaira, D. and Hayette, M.P. (2014) Implementation of an In-House Quantitative Real-Time PCR for Determination of HIV Viral Load in Kinshasa. Open Access Library Journal, 1, e855. https://doi.org/10.4236/oalib.1100855
[15]
Kamangu, N.E., Chatté, A., Boreux, R., Susin, F., Kalala, L.R., Mvumbi, L.G., De Mol, P., Hayette, M.P. and Vaira, D. (2015) Comparison of an In-House Quantitative PCR and COBAS Ampliprep/TaqMan Roche for Determination of Viral Load for HIV Type 1 Non-B. Open Access Library Journal, 2, e1402. https://doi.org/10.4236/oalib.1101402
[16]
Bongenya, B.I., Bukongo, R.N., Bulanda, B.I., Chuga, D., Kabasele, J.Y.K., Okonda, M.O., Tshisumbu, C. and Kamangu, N.E. (2018) Gender Difference in Early Treatment Patients for Human Immunodeficiency Virus Type 1 Infection in Kinshasa, Democratic Republic of Congo. Mathews Journal of HIV/AIDS, 3, Article No.18.
[17]
Wateba, I.N.M., Patassi, A.A., Balaka, A. and Tidjani, O. (2013) Viral Characteristic of HIV Infected Patients Naïf of Anti-Retroviral Therapy with CD4+ T Lymphocytes Rate Greater than 350 per Microliter of Blood in Lomé Togo. World Journal of AIDS, 3, 364-366. https://doi.org/10.4236/wja.2013.34047
[18]
Egger, M., May, M., Chêne, G., Phillips, A.N., Ledergerber, B., et al. (2002) Prognosis of HIV-1-Infected Patients Starting Highly Active Therapy: A Collaborative Analysis of Prospective Studies. The Lancet, 360, 119-129. https://doi.org/10.1016/S0140-6736(02)09411-4
[19]
Phair, J.P., Mellors, J.W., Detels, R., Margolick, J.B. and Muñoz, A. (2002) Virologic and Immunologic Values Allowing Safe Deferral of Antiretroviral Therapy. AIDS, 16, 2455-2459. https://doi.org/10.1097/00002030-200212060-00011
[20]
Bulanda, B.I., Bongenya, B.I., Chatte, A., Kateba, E.T., Kabasele, J.-Y.D., Omakoy, M.O., Chuga, D., Tshibumbu, C., Mwanaut, I. and Kamangu, E.N. (2020) Molecular Diversity of the Human Immunodeficiency Virus Type 1 in Metropolitan Cities in Central Africa: An Update of Data. World Journal of AIDS, 10, 80-93. https://doi.org/10.4236/wja.2020.102007
[21]
Jordan, M.R., Winsett, J., Tiro, A., Bau, V., Berbara, R.S., Rowley, C., Bellosillo, N., Wanke, C. and Coakley, E.P. (2013) HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels. World Journal of AIDS, 3, 71-78. https://doi.org/10.4236/wja.2013.32010
[22]
Guillaume, L.Y., Yessé, Z.N., Hortense, K., Laurent, D., Arsher, C.M., Joseph, L.S. and Marie-Chantal, A.K. (2012) Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d’Ivoire. World Journal of AIDS, 2, 57-63. https://doi.org/10.4236/wja.2012.22008
[23]
Kamangu, E.N. (2020) Diversité Génétique du VIH à Kinshasa, République Démocratique du Congo: Défis d’une dynamique évolutive. Editions Universitaires Européennes, Republic of Moldova.
[24]
Programme National de Lutte Contre le VIH/SIDA et les IST (PNLS), Ministère de la Santé Publique, République Démocratique du Congo (2019) Révision du Guide National de Prise en Charge. https://www.pnls-rdc.org/
[25]
Bongenya, B.I., Sombo, M.-T.A.S., Bumoko, G.M.M., Kabengele, B.O., Lusakibanza, M.M., Mesia, G.K. and Kamangu, E.N. (2023) Compliance with First-Line Antiretroviral Treatment (ART) for HIV Infection in the Era of Dolutegravir in Kinshasa, Democratic Republic of Congo. World Journal of AIDS, 13, 11-17. https://doi.org/10.4236/wja.2023.131002
